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Action Plan for Drug-Resistant
Streptococcus pneumoniae
Streptococcus pneumoniae is a leading cause of
illness and death in the United States. It accounts
for an estimated 3,000 cases of meningitis, 50,000
cases of bacteremia, 500,000 cases of pneumonia,
and more than seven million cases of otitis media
annually (1, 2). S. pneumoniae had been almost
uniformly susceptible to penicillin; however, with the
development and worldwide spread of drug-resistant
S. pneumoniae (DRSP), a public health challenge has
emerged. Studies from Australia, Southeast Asia,
Africa, and Europe have reported pneumococcal
strains resistant to penicillin and other drugs (3).
Surveillance data collected at the Centers for Dis-
ease Control and Prevention (CDC) have shown that
high-level resistance to penicillin increased more
than 60-fold—from 0.02% for 1979-1987 to 1.3% in
1992—for pneumococcal isolates from invasive infec-
tions (4). In some communities, at least 30% of iso-
lates are nonsusceptible to penicillin (5; CDC,
unpublished data).
Pneumococcal resistance has been reported for
beta-lactams, macrolides, chloramphenicol, and sul-
fonamides. As multidrug-resistant strains become
increasingly prevalent, treatment options will be-
come limited. The clinical impact of antimicrobial
resistance on the outcome of invasive and noninva-
sive DRSP infections remains largely unknown. Van-
comycin has been required to treat patients with
pneumococcal meningitis caused by strains resistant
to extended-spectrum cephalosporins (e.g., cefotaxime
and ceftriaxone) (6). Optimal treatment regimens for
DRSP infections remain to be defined; CDC is organiz-
ing a working group to develop consensus guidelines
for the management of pneumococcal infections.
The prevalence of pneumococcal resistance to an-
timicrobial drugs is not known for most areas of the
United States since DRSP infection has not been a
reportable condition. Some studies have suggested
great geographic and temporal variation in levels of
resistance; prevalence rates are 2% to 30% (5,7). In
addition, DRSP can spread rapidly through a popu-
lation, and the prevalence of resistant isolates can
differ in adults and children. To make appropriate
empiric antimicrobial choices, clinicians need a reli-
able and current assessment of the level of antimi-
crobial resistance in the community.
To address the growing problem of DRSP, a work-
ing group of public health practitioners, health care
providers, clinical laboratorians, and repre-
sentatives of key professional societies was formed
in June 1994. The group identified the development
of an electronic, laboratory-based surveillance sys-
tem for DRSP as the essential first step to address
this concern. The group has issued a comprehensive
plan, “A National Strategy for the Surveillance, Ap-
plied Research, Control, and Prevention of DRSP,” to
be published in June 1995. This plan focuses on three
public health priorities: 1) to define and monitor the
prevalence and geographic distribution of DRSP and
recognize the emergence of patterns of resistance, 2)
to study further the epidemiology of DRSP, and 3) to
minimize the complications of DRSP infections
through control and prevention.
The working group has begun piloting an elec-
tronic, laboratory-based surveillance network to de-
tect serious illness due to DRSP. For isolates
nonsusceptible to oxacillin (zone size <20 mm), mini-
mal inhibitory concentrations should routinely be
determined for penicillin, an extended-spectrum
cephalosporin, chloramphenicol, vancomycin, and
other clinically relevant drugs. These data will be
analyzed to determine community-specific levels of
resistance and will be made available to clinicians to
improve antimicrobial use. Additionally, aggregate data
will be sent to CDC so that national trends in pneumo-
coccal resistance can be identified and reported.
Clinical laboratory directors, large commercial
laboratory operators, and laboratory software manu-
facturers indicate that many laboratory software
systems can accommodate a paperless, automated
mechanism for reporting communicable disease in-
formation directly to public health authorities.
DRSP surveillance may thus serve as a model for
electronic, laboratory-based reporting for other labo-
ratory-reportable conditions. Although improved
data flow should increase the number and timeliness
of reported cases, a strategy for ensuring quality
control of data will be required. 
In the era of emerging antimicrobial resistance,
prevention of pneumococcal infections is paramount;
vaccination strategies offer an important approach
to controlling DRSP. An existing pneumococcal poly-
saccharide vaccine that can prevent a substantial
number of pneumococcal infections, including those
caused by DRSP, is underutilized. The vaccine is
recommended by the Advisory Committee for Immu-
nization Practices (ACIP) for use in persons older
than 2 years of age who have certain underlying
medical conditions and for all persons older than 65
years of age (8). It is not recommended for routine
use among children under 2 years of age because it
does not provide immunity consistently in this age
group. An effective vaccine is needed to prevent
pneumococcal infections in this population, which
has the highest risk for otitis media and meningitis
caused by DRSP. If the prevalence of pneumococcal
infection (and therefore antimicrobial use) can be
substantially reduced by vaccination, the impact of
DRSP may diminish. Novel vaccine demonstration
projects supported by federal and state health agen-
cies are under way to explore means of increasing
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Applied research is also needed to address the
problem of DRSP. CDC has recently funded popula-
tion-based investigations to define risk factors, pat-
terns of transmission, costs, and health outcomes
associated with DRSP. Public health programs for
control and prevention of DRSP are being designed
for use at local, state, and federal levels. Because
unnecessary use of antimicrobial agents has contrib-
uted to the emergence of resistant bacteria (1, 3, 5),
educational materials and campaigns are being de-
veloped for both health care providers and consum-
ers to raise awareness of the link between excessive
antimicrobial use and the emergence of drug-resis-
tant organisms. Through a multifaceted approach,
the growing problem of DRSP can be addressed to
minimize the complications and costs of resistant
pneumococcal infections. Surveillance for DRSP is
an important starting point from which control and
prevention solutions can proceed.
For more information regarding DRSP activities at
CDC, write to Division of Bacterial and Mycotic Dis-
eases, NCID, CDC Mailstop C-09, 1600 Clifton Rd.,
Atlanta, GA 30333 or send an e-mail to
DRSP@ciddbd1.em.cdc.gov.
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